Ulcerative ColitisPhase 3NCT02435992
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
A Phase 3 study testing RPC1063 in people with Ulcerative Colitis, run by Celgene at 372 sites in 30 countries.
Trial summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Ulcerative Colitis
- What is being tested?
- RPC1063
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,012 participants
- Where
- 372 sitesin 30 countries
- Study dates
- 17 Jun 2015to 17 Jun 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 to 75 years (at screening for Cohort 1 and 2)
- UC confirmed on endoscopy
- Moderately to severely active UC (May score 6-12)
- Currently receiving treatment with aminosalisylate, prednisone, or budesonide
- Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization
Who cannot join
- Have severe extensive colitis as evidence by:
- Physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline.
- Current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation.
- Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis
- Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk
- History of uveitis or unknown macular edema
- Pregnancy, lactation, or a positive serum β-human chorionic gonadotropin (β-hCG) measured during screening
Trial locations and contacts
372 sites in 30 countries.
372 sites in 30 countries
United States113 sites
Anaheim Clinical Trials
Anaheim, California, 92801
University of Michigan Health System
Ann Arbor, Michigan, 48109
Asheville Gastroenterology Associates, P.A.
Asheville, North Carolina, 28801
Atlanta Gastroenterology Associates LLC
Atlanta, Georgia, 30342
University of Maryland Medical Group
Baltimore, Maryland, 21201
Woodholme Gastroenterology
Baltimore, Maryland, 21209
Johns Hopkins Clinical Research Network
Baltimore, Maryland, 21287
Gastroenterology Associates, LLC
Baton Rouge, Louisiana, 70809
Ehrhardt Clinical Research, LLC
Belton, Missouri, 64012
Boston Medical Center
Boston, Massachusetts, 02118
Clinical Research Professionals, LLC - De Paul Medical Dr
Bridgeton, Missouri, 63044
Commonwealth Clinical Studies, PLLC.
Brockton, Massachusetts, 02302
NY Scientific
Brooklyn, New York, 11235
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7305
Carolinas HealthCare System Digestive Health
Charlotte, North Carolina, 28204
University of Virginia
Charlottesville, Virginia, 22908
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, 23320
Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
Northwestern University Feinberg Sch of Medicine Division of Gastroenterology
Chicago, Illinois, 60611
University of Chicago Medical Center
Chicago, Illinois, 60637-1447
UC Health Clinical Trials Office
Cincinnati, Ohio, 45206
Gastro Florida
Clearwater, Florida, 33756-3839
Clinical Research of West Florida Inc - Clearwater
Clearwater, Florida, 33765
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Gastro Center of Maryland
Columbia, Maryland, 21045
Consultants in Gastroenterology, PA
Columbia, South Carolina, 29203
Ohio State University Clinical Trials Management Office
Columbus, Ohio, 43210
Aurora Care Clinic
Costa Mesa, California, 92627
Baylor Research Institute
Dallas, Texas, 75246-1613
Advanced Pharma Research, Inc
Delray Beach, Florida, 33445
Universal Axon Clinical Research
Doral, Florida, 33166
Dolphin Medical Research
Doral, Florida, 33172
Brooke-Army Medical Center
Fort Sam Houston, Texas, 78234
Ventavia Research Group, LLC
Fort Worth, Texas, 76104
Valley View Internal Medicine
Garden Grove, California, 92843
Gastro One
Germantown, Tennessee, 38138
Long Island Clinical Research Associates
Great Neck, New York, 11021
Medical Research Center of Connecticut, LLC
Hamden, Connecticut, 06518
South Florida Clinical Trials
Hialeah, Florida, 33016
Gulf Coast Research Group LLC
Houston, Texas, 77004
The Methodist Hospital Research Institute
Houston, Texas, 77030
Houston Endoscopy and Research Center
Houston, Texas, 77079
Davita Clinical Trials, LLC
Huntington Beach, California, 92646
Grand Teton Research Group, PLLC
Idaho Falls, Idaho, 83404
Indiana University Hospital
Indianapolis, Indiana, 46202
East Carolina Gastroenterology, PA
Jacksonville, North Carolina, 28546
Kinston Medical Specialists, PA
Kinston, North Carolina, 28501
University of California San Diego Medical Center
La Jolla, California, 92037
OM Research
Lancaster, California, 93534
Florida Center for Gastroenterology
Largo, Florida, 33777
Mary Hitchcock Memorial Hospital
Lebanon, New Hampshire, 07756
University of Kentucky Medical Center
Lexington, Kentucky, 40504
University of Southern California - Keck School of Medicine
Los Angeles, California, 90033
Southern California Research Institute Medical Group, Inc.
Los Angeles, California, 90045
Gastrointestinal Biosciences
Los Angeles, California, 90067
UCLA Medical Center
Los Angeles, California, 90095
University of Louisville
Louisville, Kentucky, 40202
Gastrointestinal Specialists of Georgia, PC
Marietta, Georgia, 30060
Community Clinical Research Network
Marlborough, Massachusetts, 01752
City Medical Group
Miami, Florida, 33126
Advanced Clincial Research
Miami, Florida, 33134
Advanced Clinical Research of Miami
Miami, Florida, 33155
Regenerate Clinical Trials
Miami, Florida, 33155
Facey Medical Foundation (Parent)
Mission Hills, California, 91345
Advanced Research for Health Improvement
Naples, Florida, 34109
Vanderbilt University Medical Center
Nashville, Tennessee, 37203
Advanced Research Institute, Inc.
New Port Richey, Florida, 34653
NSB Research
New Smyrna Beach, Florida, 32168
Icahn School of Medicine Mount Sinai Beth Isreal
New York, New York, 10003
Concord Medical Group PRIME
New York, New York, 10016
New York University School of Medicine
New York, New York, 10016
Weill Cornell Medical College
New York, New York, 10021
Mount Sinai - PRIME
New York, New York, 10029
Arkansas Gastroenterology, P.A.
North Little Rock, Arkansas, 72117
Harmony Clinical Research
North Miami Beach, Florida, 33162
Med-Care Research
North Miami Beach, Florida, 33162
DM Clinical Research
Oak Lawn, Illinois, 60453-3767
Alliance Clinical Research, LLC
Oceanside, California, 92056-4497
University of Oklahoma
Oklahoma City, Oklahoma, 73104
Digestive Disease Specialists
Oklahoma City, Oklahoma, 73112
Gastroenterology Associates of Orangeburg
Orangeburg, South Carolina, 29118
Center For Digestive Health
Orlando, Florida, 32803
IMIC, Inc.
Palmetto Bay, Florida, 33157
DBC Research, Corp
Pembroke Pines, Florida, 33029
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4206
Theia Clinical Research, LLC
Pinellas Park, Florida, 33781
Oregon Health & Science University
Portland, Oregon, 97239
Mayo Clinic
Rochester, Minnesota, 55905
PMG Research of Rocky Mount, LLC
Rocky Mount, North Carolina, 27804
University of Utah
Salt Lake City, Utah, 84132
Gastroenterology Research of San Antonio, LLC
San Antonio, Texas, 78229
San Antonio Gastroenterology
San Antonio, Texas, 78229
Medical Associates Research Group, Inc.
San Diego, California, 92123
University of California at San Francisco (PARENT)
San Francisco, California, 94115
Benaroya Research Institute at Virginia Mason
Seattle, Washington, 98101
University of Washington Medical Center
Seattle, Washington, 98109
Texas Digestive Disease Consultants - Southlake
Southlake, Texas, 76092
Spring Gastroenterology
Spring, Texas, 77379
Mercy Research
Springfield, Missouri, 65806
Clinical Inquest Center Ltd
Springfield, Ohio, 45504
Washington University
St Louis, Missouri, 63110
Clinical Research Professionals LLC - The Pines Court
St Louis, Missouri, 63141
Clinical Research Professionals, LLC - Olde Cabin Rd
St Louis, Missouri, 63141
Arizona Digestive Health
Sun City, Arizona, 85351
Montefiore Medical Center
The Bronx, New York, 10467
Cotton-O'Neil Clinical Research Center, Digestive Health
Topeka, Kansas, 66606
Charm City Research Group
Towson, Maryland, 21204
Center For Digestive Health
Troy, Michigan, 48098
Adobe Clinical Research LLC
Tucson, Arizona, 85712
Digestive Health Specialists of Tyler
Tyler, Texas, 75701
Carle Foundation Hospital
Urbana, Illinois, 61801
Gastroenterology, LTD
Virginia Beach, Virginia, 23454
Florida Medical Clinic, P.A.
Zephyrhills, Florida, 33613
Ukraine29 sites
RCI Chernivtsi Regional Clinical Hospital Dept of Gastroenterology Bukovinsky SMU
Chernivtsi, 58002
Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital
Dnipropetrovsk, 49027
Si Institute Of Gastroenterology Of Namsu Dept Of Stomach And Duodenum Diseases
Dnipropetrovsk, 49074
Ivano-Frankivsk City Clinical Hospital #1 Dep of Surgery SHEI Ivano-Frankivsk NMU
Ivano-Frankivsk, 76014
Central City Clinical Hospital Dept of Theraphy No. 2 SHEI Ivano-Frankivsk NMU
Ivano-Frankivsk, 76018
CI of PH Kharkiv CCH #2
Kharkiv, 61037
GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine
Kharkiv, 61039
Kyiv City Clinical Hospital #1
Kyiv, 02091
SI Republican Clinical Hospital of the MOHU Dept of Gastroenterology O.O.Bogomolets NMU
Kyiv, 04053
CI of Kyiv RC Regional Clinical Hospital #2
Kyiv, 04073
Kyiv CCH #8 Dept of Gastroenterology P.L. Shupyk NMA of PGE
Kyiv, 04201
Kyiv CCH #18 Dept of Proctology O. O. Bogomolets NMU
Kyiv, 1030
Lviv Regional Clinical Hospital
Lviv, 79010
Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU
Lviv, 79059
CI Sumy City Clinical Hospital #1 Dept of Therapy Sumy SU
Sumy, 40021
Sumy Regional Clinical Hospital
Sumy, 40022
CI of TRC Ternopil University Hospital
Ternopil, 46002
A. Novak Transcarpathian Regional Clinical Hospital
Uzhhorod, 88018
MCIC MC LLC Health Clinic
Vinnytsia, 02029
Vinnytsia Regional Clinical Hospital for Invalids of the Great Patriotic War
Vinnytsia, 21005
M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU
Vinnytsia, 21018
Vinnytsia M.I. Pyrohov Regional Clinical Hospital
Vinnytsia, 21018
Vinnytsia M.I. Pyrohov National Medical University
Vinnytsia, 21029
City Clinical Hospital of Emergency and Urgent Care of Zaporizhzhya
Zaporizhia, 69000
Zaporizhia City Multispecialty Clinical Hospital #9, Department of Neurology
Zaporizhia, 69065
CI City Hospital #1
Zaporizhia, 69104
CI Zapor City Multifunctional CH#9 City Center of Gastroenterology SI Zapor MA of PGE of MOHU
Zaporizhzhya, 69065
Zaporizhia Regional Clinical Hospital
Zaporizhzhya, 69600
Central District Hospital under Zhytomyr District Council
Zhytomyr, 12430
Russia20 sites
Multidisciplinary Medical Clinic "Anthurium"
Barnaul, 656043
Road Clinical Hospital on Station Irkutsk-Passazhirskiy of OJSC Russian Railways
Irkutsk, 664005
SBEI HPE "Kazan State Medical University" of the MoH of the RF
Kazan', 420012
FSBIH "Central Clinical Hospital of Russian Academy of Sciences"
Moscow, 119333
SBIH of Nizhniy Novgorod region " Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko"
Nizhny Novgorod, 603126
SBEIHPE Novosibirsk State Medical University
Novosibirsk, 630054
FSBI "Scientific Research Institute of Physyology and Basic Medicine" under the SB of RAMS
Novosibirsk, 630117
BHI of Omsk region "Clinical Oncology Dispensary"
Omsk, 644013
SBEI HPE Rostov State Medical University of the MoH of the RF
Rostov-on-Don, 344022
SPb SBIH Alexandrovskaya City Hospital
Saint Petersburg, 193312
FFSBI "The Nikiforov Russian Center of Emergency and Radiation Medicine"
Saint Petersburg, 194044
FSMEI HPE "Military Medical Academy n.a. S.M.Kirov"of Ministry of Defense of Russia
Saint Petersburg, 194044
SBIH City Clinical Hospital #31
Saint Petersburg, 194291
SPb SBIH City Hospital # 26
Saint Petersburg, 196247
Pavlov First Saint Petersburg State Medical University
Saint Petersburg, 197022
Union Clinic
Saint-Peterburg, 191119
Private Educational Institution of Higher Education "Medical University "REAVIZ"
Samara, 443011
LLC Medical Company Hepatologist
Samara
SBEI HPE "Stavropol State Medical Academy" MoH of RF
Stavropol, 355017
Regional Clinical Hospital
Vladimir, 600023
Poland17 sites
Clinsante S.C. Osrodek Badan Klinicznych
Bydgoszcz, 85-794
Specjalistyczna Przychodnia Lekarska Medicus
Chorzów, 41-500
GLOBE Clinical Research Sp. z o.o. LLC
Kłodzko, 57-300
PLEJADY Sp. z o.o. (LLC) Medical Centre
Krakow, 30-363
Centrum Medyczne A-Z Clinic
Krakow, 31-315
Healthcare Center Orkan Med Stec Michalska Spolka Jawna
Ksawerów, 95-054
Santa Familia Centrum Badan, Profilaktyki i Leczenia
Lodz, 90-302
KO-MED Centra Kliniczne Lublin II
Lublin, 20-362
Trialmed Llc
Piotrkow Trybunalski, 97-300
SOLUMED Centrum Medyczne
Poznan, 60-529
Specjalistyczna Praktyka Lekarska dr med. Marek Horynski
Sopot, 81-756
KO-MED Centra Kliniczne Staszow
Staszów, 28-200
GASTROMED Kopon, Zmudzinski and Partners Specialist Centre for Gastroenterology and Endoscopy, Spe
Torun, 87-100
MDM Healthcare Centre
Warsaw, 00-632
Nzoz Vivamed
Warsaw, 03-580
Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice
Wierzchosławice, 33-122
LexMedica Osrodek Badan Klinicznych
Wroclaw, 53-114
Germany16 sites
Charite - Universitaetsmedizin Berlin Charité - Campus Benjamin Franklin
Berlin, 12203
Charite - Campus Virchow-Klinikum
Berlin, 13353
DRK Kliniken Berlin Westend
Berlin, 14050
Universitaetsklinikum Koeln
Cologne, 50937
Medical Care Unit Dachau
Dachau, 85221
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, 01307
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt, 60590
Crohn Colitis Centrum Rhein Main
Frankfurt, 60594
Universitaetsklinikum Freiburg
Freiburg im Breisgau, 79106
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, 20426
Asklepios Klinik Hamburg
Hamburg, 22559
Medizinische Hochschule Hannover
Hanover, 30625
EUGASTRO GmbH
Leipzig, 4103
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
Lübeck, 23538
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, 55131
Universitatsklinikum Ulm
Ulm, 89081
South Korea16 sites
Inje University Haeundae Paik Hospital
Busan, 612-030
Yeungnam University Hospital
Daegu, 42415
Konyang University Hospital
Daejeon, 302-718
Hanyang Univerisy Guri Hospital
Guri-si, 471-701
Seoul National University Bundang Hospital
Seongnam, 463-707
CHA Bundang Medical Center CHA University
Seongnam-si, 13496
Kyung Hee University Hospital
Seoul, 02447
Seoul National University Hospital
Seoul, 110-744
Samsung Medical Center
Seoul, 135-710
Korea University Anam Hospital
Seoul, 136-705
Asan Medical Center
Seoul, 138-736
Kangbuk Samsung Hospital
Seoul, 3181
Severance Hospital, Yonsei University
Seoul, 3722
Ewha Womans University Mokdong Hospital
Seoul, 7985
The Catholic University of Korea, St.Vicent's Hospital
Suwon, 442-723
Yonsei University Wonju Severance Christian Hospital
Wŏnju, 220701
Bulgaria15 sites
Medical Centre "Asklepii", OOD
Dupnitsa, 2600
UMHAT 'Dr. Georgi Stranski', EAD
Pleven, 5800
UMHAT "Kaspela", EOOD
Plovdiv, 4002
MC Rusemed ltd.
Rousse, 7013
NMTH "Tsar Boris III"
Sofia, 1233
MHAT "Lyulin", EAD
Sofia, 1336
City Clinic UMHAC EOOD
Sofia, 1407
MHAT 'Tokuda Hospital Sofia', EAD
Sofia, 1407
UMHAT 'Tsaritsa Yoanna - ISUL', EAD
Sofia, 1527
Fourth MHAT - Sofia EAD
Sofia, 1606
UMHAT 'Sveta Anna' AD
Sofia, 1750
UMHAT "SofiaMed", OOD
Sofia, 1797
Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
Stara Zagora, 6000
MHAT 'Sv. Marina', EAD
Varna, 9010
MC Medica Plus
Veliko Tarnovo, 5000
Hungary14 sites
DRC Gyogyszervizsgalo Kozpont Kft
Balatonfüred, 8230
Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz
Békéscsaba, 5600
Obudai Egeszsegugyi Centrum Kft.
Budapest, 1036
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, 1062
Semmelweis Egyetem
Budapest, 1083
Pannonia Maganorvosi Centrum
Budapest, 1136
Szent Margit Korhaz
Budapest, H-1032
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
Gyula, 5700
Somogy Megyei Kaposi Mor Oktato Korhaz
Kaposvár, 7400
Vasutegeszsegugyi Kft. - Debreceni Egeszsegugyi Kozpont
Létavértes, 4281
Mohacsi Korhaz
Mohács, 7700
SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
Nyíregyháza, 4400
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
Székesfehérvár, 8000
Canada12 sites
Brandon Medical Arts Clinic
Brandon, Manitoba, R7A 0N7
Centre integre de sante et de services sociaux de la Monteregie-Centre - Hopital Charles-Le Moyne
Greenfield Park, Quebec, J4V 2H1
Viable Clinical Research - Lindsay
Lindsay, Ontario, K9V 5G6
LHSC - University Hospital
London, Ontario, N6A 5A5
LHSC - Victoria Hospital
London, Ontario, N6A 5W9
The Ottawa Hospital - General Campus
Ottawa, Quebec, K1H 8L6
CHUS - Hôpital Fleurimont
Sherbrooke, Quebec, J1H5N4
Humber River Hospital
Toronto, Ontario, M3M 0B2
Mount Sinai Hospital
Toronto, Ontario, M5T 3L9
Toronto Liver Centre
Toronto, Ontario, M6H 3M1
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9
Toronto Digestive Disease Associates, Inc.
Vaughan, Ontario, L4L 4Y7
Italy12 sites
Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi
Bologna, 40138
Azienda Ospedaliera Universitaria Careggi
Florence, 50134
Azienda Ospedaliero Universitaria San Martino
Genova, 16132
Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale Sacco
Milan, 20157
A.O.U. Policlinico di Modena
Modena, 41124
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
Monza, 20900
Azienda Ospedaliera Universitaria "Federico II"
Naples, 80131
Fondazione IRCCS Policlinico San Matteo
Pavia, 27100
Azienda Ospedaliero Universitaria Pisana
Pisa, 56124
Complesso Integrato Columbus
Roma, 00168
Istituto Clinico Humanitas
Rozzano (MI), 20089
IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo FG, 71013
Slovakia11 sites
Fakultna nemocnica s poliklinikou F.D. Roosevelta
Banská Bystrica, 97517
Alian s.r.o.
Bardejov, 08501
PRO SANUS, a.s., Poliklinika ProCare Central
Bratislava, 82107
IBDcentrum s.r.o.
Bratislava, 83104
Slovak Research Center-team member, Sukromna gastroenterologicka ambulancia
Ilava, 01901
Gastroped s.r.o.
Košice, 040 01
Gastroeneterologicka ambulancia MUDr. Peter Hegyi, s.r.o.
Malacky, 90122
PIGEAS s.r.o.
Martin, 3601
Nemocnica s poliklinikou S. Kukuru Michalovce, a.s.
Michalovce, 7101
Gastromedic s.r.o.
Nové Zámky, 94002
EndoCorp s.r.o.
Trnava, 917 75
Australia9 sites
Royal Adelaide Hospital
Adelaide, South Australia, 5000
Monash Medical Centre Clayton
Bentleigh East, 3165
Royal Prince Alfred Hospital
Camperdown, 2050
Centre For Digestive Diseases
Five Dock, New South Wales, 2046
Nepean Hospital
Kingswood, New South Wales, 2751
Cabrini Hospital Malvern
Malvern, Victoria, 3144
The Alfred Hospital
Melbourne, Victoria, 3004
Mater Hospital Brisbane
South Brisbane, Queensland, 4101
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
Czechia9 sites
Vojenska nemocnice Brno
Brno, 63600
Hepato-Gastroenterologie HK, s.r.o.
Hradec Králové, 50012
GASTRO JeKa s.r.o.
Klatovy, 399 01
Gregar s.r.o.
Olomouc, 779 00
PreventaMed
Olomouc, 77900
Institut klinicke a experimentalni mediciny
Prague, 14021
Thomayerova nemocnice
Prague, 14059
ISCARE, a.s.
Prague, 190 00
Nemocnice Slany
Slaný, 274 01
Serbia8 sites
Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine
Belgrade, 11 080
Clinical Center of Serbia, Clinic of Gastroenterology and Hepatology, Department of Gastroenterology
Belgrade, 11000
Clinical Hospital Center Zvezdara Clinic of Internal Diseases
Belgrade, 11000
Military Medical Academy, Clinic of Gastroenterology and Hepatology
Belgrade, 11000
Clinical Hospital Center Zemun Department of Gastroenterology
Belgrade, 11080
Clinical Center Kragujevac, Clinic of Internal Medicine, Center for Gastroenterohepatology
Kragujevac, 34000
Clinical Center Nis, Clinic of Gastroenterology and Hepatology
Niš, 18 000
General Hospital Djordje Jovanovic Zrenjanin
Zrenjanin, 23 000
Romania7 sites
Bacau County Emergency Hospital, Department of Gastroenterology
Bacau, 600114
Hyperclinica MedLife Grivita
Bucharest, 010719
Bucharest University Emergency Hospital, Department of Internal Medicine II
Bucharest, 050098
TVM MED SERV SRL, Medical Center for Gastroenterology, Hepatology and Digestive Endoscopy
Cluj-Napoca, 400132
Sf. Apostol Andrei Constanta Emergency Clinical County Hospital
Constanța, 900591
Craiova County Emergency Clinical Hospital
Craiova, 200642
"Pius Brinzeu" County Emergency Clinical Hospital, Department of Gastroenterology and Hepatology
Timișoara, 300723
Israel6 sites
Wolfson Medical Center
Holon, 58100
Shaare Zedek Medical Center
Jerusalem, 91031
Meir Medical Center
Kfar Saba, 44281
Chaim Sheba Medical Center
Ramat Gan, 52621
Kaplan Medical Center
Rehovot, 76100
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
Netherlands6 sites
Vrije Universiteit Medisch Centrum (VUMC)
Amsterdam, 1081 HV
Academisch Medisch Centrum
Amsterdam, 1105 AZ
Universitair Medisch Centrum Groningen (UMCG)
Groningen, 9700 RB
Maastricht University Medical Center
Maastrich, 6202 AZ
Zuyderland Medisch Centrum - Sittard-Geleen
Sittard-Geleen, 6162 BG
ETZ Elisabeth
Tilburg, 5022 GC
South Africa6 sites
Dr MJ Prins Practice
Cape Town, 7500
Tiervlei Trial Centre
Cape Town, 7550
Endocare Research
Cape Town, 7646
Dr JP Wright Practice
Cape Town, 7708
Dr YS Nanabhay Practice
Johannesburg, 2193
Emmed Research
Pretoria, 0084
United Kingdom6 sites
University Hospital Coventry
Coventry, CV2 2DX
Royal Devon and Exeter Hospital (Wonford)
Exeter, EX2 5DW
Gloucestershire Royal Hospital
Gloucester, GL1 3NN
Whipps Cross University Hospital
London, E11 1NR
St Thomas' Hospital
London, SE1 7EH
Royal Shrewsbury Hospital
Shrewsbury, SY38XQ
Argentina5 sites
Hospital Italiano
Buenos Aires, C1181ACH
Instituto DAMIC Fundacion Rusculleda
Córdoba, X5003DCE
Hospital Italiano de La Plata
La Plata, 01900
Instituto Medico CER
Quilmes, B1878DVB
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, 2000
Belgium5 sites
Imeldaziekenhuis
Bonheiden, 2820
AZ Maria Middelares
Ghent, 9000
Universitair Ziekenhuis Gent
Ghent, 9000
UZ Leuven
Leuven, 3000
CHC - Clinique St-Jospeh
Liège, 4000
Croatia5 sites
Clinical Hospital Center Osijek
Osijek, 31000
Clinical Hospital Centre Rijeka
Rijeka, 51000
Clinical Hospital "Sveti Duh", Clinic of Internal Diseases
Zagreb, 10000
Clinical Hospital Center Sestre milosrdnice Clinic of Internal Diseases
Zagreb, 10000
Clinical Hospital Dubrava, Clinic of Internal Medicine, Department of Gastroenterology
Zagreb, 10000
Georgia5 sites
LTD Research Institute of Clinical Medicine
Tbilisi, 0112
LLC Vivamedi
Tbilisi, 0131
LTD Academician N.Kipshidze Central University Clinic
Tbilisi, 0160
LTD Aversi Clinic
Tbilisi, 0160
LTD Coloproctological Center
Tbilisi, 0160
Greece5 sites
Laiko General Hospital of Athens
Athens, 11 527
University General Hospital of Heraklion
Heraklion, 715 00
University General Hospital of Larissa
Larissa Thessaly, 41110
General Hospital of Thessaloniki Hippokration
Thessaloniki, 54642
424th Army General Hospital
Thessaloniki, 56429
Moldova4 sites
"Sfanta Treime" Clinical Municipal Hospital
Chisinau, MD-2068
Clinical Hospital of the Ministry of Health, Department of Endoscopic Surgery
Chisinau, MD2005
"Sf. Arhanghel Mihail" Municipal Clinical Hospital
Chisinau, MD2025
Republican Clinical Hospital
Chisinau, MD2025
Spain4 sites
University Hospital Germans Trias i Pujol
Badalona, 08916
Hospital Universitario de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, 35012
University Hospital of the Canary Islands (HUC) La Laguna
San Cristóbal de La Laguna, 38320
University Hospital Virgen del Rocio
Seville, 41013
Belarus3 sites
Gomel Regional Clinical Hospital
Homyel, 246029
City Clinical Hospital No 10
Minsk, 220096
Vitebsk Regional Clinical Hospital
Vitebsk, 210037
New Zealand2 sites
Christchurch Hospital NZ
Christchurch, 8011
Dunedin Public Hospital
Dunedin, 9016
About this study
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
Read the detailed description
The trial is composed of 2 periods: Induction and Maintenance. In the Induction Period (IP), patients will be entered into the trial in 2 separate cohorts (Cohort 1 and Cohort 2).Patients from Cohort 1 and 2 in clinical response at the end of the IP will proceed through to the Maintenance Period (MP). Patients from Cohort 1 and 2 who participate in this trial may also qualify to participate in an optional Open-Label Extension (OLE) trial.
- Conditions
- Ulcerative Colitis
- Being tested
- RPC1063, Placebo
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RPC1063Drug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| RPC1063 (Ozanimod) | Experimental | 1mg, daily oral administration during Induction and Maintenance periods. Receives: Drug: RPC1063 |
| Placebo | Placebo comparator | Daily oral administration during Induction and Maintenance periods. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants in Clinical Remission at 10 Weeks
Percentage of participants that are in Clinical remission at 10 weeks
Measured: At 10 Weeks
Percentage of Participants in Clinical Remission at 52 Weeks
Percentage of participants that are in Clinical remission at 52 weeks
Measured: At 52 Weeks
Secondary outcomes (9)
Percentage of Participants With Clinical Response at 10 Weeks
Percentage of participants that are in Clinical response at 10 weeks
Measured: At 10 Weeks
Percentage of Participants With Endoscopic Improvement at 10 Weeks
Percentage of participants with endoscopic improvement at 10 weeks
Measured: At 10 Weeks
Percentage of Participants With Mucosal Healing at 10 Weeks
Percentage of participants with mucosal healing at 10 weeks
Measured: At 10 Weeks
Percentage of Participants in Clinical Response at 52 Weeks
Percentage of participants that are in Clinical response at 52 weeks
Measured: At 52 Weeks
Percentage of Participants With Endoscopic Improvement at 52 Weeks
Percentage of participants with endoscopic improvement at 52 weeks
Measured: At 52 Weeks
Percentage of Participants in Clinical Remission at Week 52 Who Were in Remission at Week 10
Percentage of participants in clinical remission at week 52 who were in clinical remission at week 10
Measured: At 52 Weeks
Percentage of Participants With Corticosteroid Free Remission at 52 Weeks
Percentage of participants with corticosteroid free remission at 52 weeks
Measured: At 52 Weeks
Percentage of Participants With Mucosal Healing at 52 Weeks
Percentage of participants with Mucosal Healing at 52 weeks
Measured: At 52 Weeks
Percentage of Participants With Durable Clinical Remission at 52 Weeks
Percentage of participants with durable clinical remission at 52 weeks
Measured: At 52 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2015 (estimated)
- Study start17 Jun 2015
- Primary completion27 Mar 2020
- Study completion17 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Ulcerative ColitisStudies of the same condition, open and under way.
- More trials run by CelgeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,012 participants (actual)
Sponsor and investigators
- Lead sponsor
- Celgene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AnnKatrin Petersen, M.D., MSc., Study director, Celgene
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02435992
- Sponsor's protocol ID
- RPC01-3101
- Status last verified
- Aug 2021
- First submitted
- 24 Apr 2015
- Last updated
- 1 Sep 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, Petersen A, Liu Z, Mehra D, Jain A, Osterman MT, Krakovich A, Riolo JV, DeBoer E, Appio J, Sinh P, Cree BAC, Cohen JA, Irving P. Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 1;32(5):954-962. doi: 10.1093/ibd/izaf319.
PubMed 41677183Yarur A, Irving P, Siegmund B, Dubinsky MC, Ananthakrishnan AN, Regueiro M, Ungaro RC, Ritter T, Nakase H, Liu Z, Mehra D, Osterman MT, Jain A, Rubin DT, Hibi T. Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. Inflamm Bowel Dis. 2026 Jan 1;32(1):77-86. doi: 10.1093/ibd/izaf195.
PubMed 41003640Sands BE, Rubin DT, Loftus EV Jr, Wolf DC, Panaccione R, Colombel JF, Dignass A, Regueiro M, Vermeire S, Afzali A, Lawlor G, Ahmad HA, Wu H, Osterman MT, Jain A, D'Haens G. Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. Am J Gastroenterol. 2025 Oct 1;120(10):2339-2349. doi: 10.14309/ajg.0000000000003310. Epub 2025 Jan 8.
PubMed 39773524Regueiro M, Siegmund B, Horst S, Moslin R, Charles L, Petersen A, Tatosian D, Wu H, Lawlor G, Fischer M, D'Haens G, Colombel JF. Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflamm Bowel Dis. 2025 Apr 10;31(4):1010-1017. doi: 10.1093/ibd/izae136.
PubMed 39018016Sands BE, D'Haens G, Panaccione R, Regueiro M, Ghosh S, Hudesman D, Ahmad HA, Mehra D, Wu H, Jain A, Petersen A, Osterman MT, Afzali A, Danese S. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2084-2095.e4. doi: 10.1016/j.cgh.2024.03.042. Epub 2024 May 8.
PubMed 38723981Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolf DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen A, Charles L, Long M. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses. Clin Gastroenterol Hepatol. 2024 May;22(5):1067-1076.e3. doi: 10.1016/j.cgh.2023.11.018. Epub 2023 Nov 30.
PubMed 38040274Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
PubMed 34587385
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
- ClinicalTrials.gov ID
- NCT02435992
- Acronym / sponsor ID
- RPC01-3101
- Conditions
- Ulcerative Colitis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,012 participants (actual)
- Lead sponsor
- CelgeneIndustry (pharma, biotech, devices)
- Study start
- 17 Jun 2015 (actual)
- Primary completion
- 27 Mar 2020 (actual)
- Study completion
- 17 Jun 2020 (actual)
- First posted
- 6 May 2015 (estimated)
- Results
- Posted 1 Sep 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
Detailed description
The trial is composed of 2 periods: Induction and Maintenance. In the Induction Period (IP), patients will be entered into the trial in 2 separate cohorts (Cohort 1 and Cohort 2).Patients from Cohort 1 and 2 in clinical response at the end of the IP will proceed through to the Maintenance Period (MP). Patients from Cohort 1 and 2 who participate in this trial may also qualify to participate in an optional Open-Label Extension (OLE) trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| RPC1063 (Ozanimod) | Experimental | Drug: RPC10631mg, daily oral administration during Induction and Maintenance periods. |
| Placebo | Placebo comparator | Drug: PlaceboDaily oral administration during Induction and Maintenance periods. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Aged 18 to 75 years (at screening for Cohort 1 and 2)
- UC confirmed on endoscopy
- Moderately to severely active UC (May score 6-12)
- Currently receiving treatment with aminosalisylate, prednisone, or budesonide
- Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization
Key exclusion criteria (7 listed)
- Have severe extensive colitis as evidence by:
- Physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline.
- Current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation.
- Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis
- Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RPC1063 | Drug | RPC1063 (Ozanimod) |
| Placebo | Drug | Placebo |
Primary outcome
Percentage of Participants in Clinical Remission at 10 Weeks
Time frame: At 10 Weeks
Percentage of participants that are in Clinical remission at 10 weeks
Percentage of Participants in Clinical Remission at 52 Weeks
Time frame: At 52 Weeks
Percentage of participants that are in Clinical remission at 52 weeks
9 secondary outcomes
Percentage of Participants With Clinical Response at 10 Weeks
Time frame: At 10 Weeks
Percentage of Participants With Endoscopic Improvement at 10 Weeks
Time frame: At 10 Weeks
Percentage of Participants With Mucosal Healing at 10 Weeks
Time frame: At 10 Weeks
Percentage of Participants in Clinical Response at 52 Weeks
Time frame: At 52 Weeks
Percentage of Participants With Endoscopic Improvement at 52 Weeks
Time frame: At 52 Weeks
Percentage of Participants in Clinical Remission at Week 52 Who Were in Remission at Week 10
Time frame: At 52 Weeks
Percentage of Participants With Corticosteroid Free Remission at 52 Weeks
Time frame: At 52 Weeks
Percentage of Participants With Mucosal Healing at 52 Weeks
Time frame: At 52 Weeks
Percentage of Participants With Durable Clinical Remission at 52 Weeks
Time frame: At 52 Weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41677183Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, Petersen A, Liu Z, Mehra D, Jain A, Osterman MT, Krakovich A, Riolo JV, DeBoer E, Appio J, Sinh P, Cree BAC, Cohen JA, Irving P. Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 1;32(5):954-962. doi: 10.1093/ibd/izaf319.
- Derived from this study: PubMed 41003640Yarur A, Irving P, Siegmund B, Dubinsky MC, Ananthakrishnan AN, Regueiro M, Ungaro RC, Ritter T, Nakase H, Liu Z, Mehra D, Osterman MT, Jain A, Rubin DT, Hibi T. Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. Inflamm Bowel Dis. 2026 Jan 1;32(1):77-86. doi: 10.1093/ibd/izaf195.
- Derived from this study: PubMed 39773524Sands BE, Rubin DT, Loftus EV Jr, Wolf DC, Panaccione R, Colombel JF, Dignass A, Regueiro M, Vermeire S, Afzali A, Lawlor G, Ahmad HA, Wu H, Osterman MT, Jain A, D'Haens G. Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. Am J Gastroenterol. 2025 Oct 1;120(10):2339-2349. doi: 10.14309/ajg.0000000000003310. Epub 2025 Jan 8.
- Derived from this study: PubMed 39018016Regueiro M, Siegmund B, Horst S, Moslin R, Charles L, Petersen A, Tatosian D, Wu H, Lawlor G, Fischer M, D'Haens G, Colombel JF. Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflamm Bowel Dis. 2025 Apr 10;31(4):1010-1017. doi: 10.1093/ibd/izae136.
- Derived from this study: PubMed 38723981Sands BE, D'Haens G, Panaccione R, Regueiro M, Ghosh S, Hudesman D, Ahmad HA, Mehra D, Wu H, Jain A, Petersen A, Osterman MT, Afzali A, Danese S. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2084-2095.e4. doi: 10.1016/j.cgh.2024.03.042. Epub 2024 May 8.
- Derived from this study: PubMed 38040274Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolf DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen A, Charles L, Long M. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses. Clin Gastroenterol Hepatol. 2024 May;22(5):1067-1076.e3. doi: 10.1016/j.cgh.2023.11.018. Epub 2023 Nov 30.
- Derived from this study: PubMed 34587385Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
Related trials for Ulcerative Colitis
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AnnKatrin Petersen, M.D., MSc. study director
Celgene
372 sites in 30 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing RPC1063 in people with Ulcerative Colitis, run by Celgene at 372 sites in 30 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 372 sites in United States, Ukraine, Russia, Poland, Germany and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Sep 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants in Clinical Remission at 10 Weeks (time frame: At 10 Weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02435992, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2021.